Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Australia
0
South Africa
0
Listed Dossiers
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Bosutinib Hydrate
2. 918639-08-4
3. Ski-606 Monohydrate
4. Bosutinib.h2o
5. Bosutinib (hydrate)
6. 844zje6i55
7. Bosutinib Hydrate (jan)
8. 3-quinolinecarbonitrile, 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-, Hydrate (1:1)
9. 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile;hydrate
10. Bosutinib Hydrate [jan]
11. Bosutinib (as Monohydrate)
12. 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile Monohydrate
13. 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile--water (1/1)
14. Bosutinibhydrate
15. Unii-844zje6i55
16. Bosulif (tn)
17. Schembl2887945
18. Chebi:68533
19. Dtxsid20238722
20. Amy16532
21. Bcp17036
22. Hy-10158a
23. Akos027326604
24. Ac-30573
25. Bosutinib Monohydrate [orange Book]
26. Cs-0019907
27. Bosutinib (as Monohydrate) [ema Epar]
28. D09728
29. A900109
30. Q27137001
31. 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl) Propoxy]-3-quinolinecarbonitrile Monohydrate
32. 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile Monohydrate
Molecular Weight | 548.5 g/mol |
---|---|
Molecular Formula | C26H31Cl2N5O4 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 9 |
Exact Mass | 547.1753099 g/mol |
Monoisotopic Mass | 547.1753099 g/mol |
Topological Polar Surface Area | 83.9 Ų |
Heavy Atom Count | 37 |
Formal Charge | 0 |
Complexity | 734 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Bosulif |
PubMed Health | Bosutinib (By mouth) |
Drug Classes | Antineoplastic Agent |
Active Ingredient | Bosutinib monohydrate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 100mg base; eq 500mg base |
Market Status | Prescription |
Company | Wyeth Pharms |
2 of 2 | |
---|---|
Drug Name | Bosulif |
PubMed Health | Bosutinib (By mouth) |
Drug Classes | Antineoplastic Agent |
Active Ingredient | Bosutinib monohydrate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 100mg base; eq 500mg base |
Market Status | Prescription |
Company | Wyeth Pharms |
Bosulif is indicated for the treatment of adult patients with:
- newlydiagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML).
- CP, accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?